SOLOIST-WHF Post-HF Benefit Index Calculator

SOLOIST-WHF Post-HF Benefit Index: Explanation and Clinical Context The SOLOIST-WHF (Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes and Worsening Heart Failure) trial was a landmark study evaluating the dual SGLT1/2 inhibitor sotagliflozin in patients recently hospitalized for acute decompensated heart failure, with or without reduced ejection fraction. This calculator estimates the relative post-HF benefit potential based on core determinants identified in the trial: NT-proBNP, eGFR, blood pressure, heart rate, left ventricular ejection fraction, and diabetes burden. These parameters were shown to correlate with differential outcomes in cardiovascular death, hospitalization for heart failure, and renal protection.

Patients enrolled in SOLOIST-WHF demonstrated a 33% relative reduction in total HF events and cardiovascular death, with early benefit observed within weeks of initiation. The benefit was consistent across LVEF subgroups, including those with preserved ejection fraction. The derived Post-HF Benefit Index is an evidence-informed synthesis that helps clinicians contextualize potential SGLT inhibition benefit in patients post-HF hospitalization — especially those transitioning from inpatient to ambulatory care.

Clinical Significance: Higher scores suggest a more favorable physiologic profile for SGLT inhibitor therapy, representing lower congestion, better renal function, and more stable hemodynamics — all associated with greater reduction in recurrent HF events and mortality.